Clinical Trial Update: Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports results for the combination of ibrutinib and nivolumab in patients with previously treated metastatic renal cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• OPDIVO (nivolumab)

Snippet

Sponsor: University of California, Davis | Conditions: Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-10